BBIO
BRIDGEBIO Says Oral Infigratinib Cut Ear Infections, Stabilized Sleep Apnea
New exploratory PROPEL 3 data show benefits beyond height growth as BridgeBio awaits FDA review of its achondroplasia drug, with a U.S. launch planned for mid-2027.
BBIO
Market-moving news on BridgeBio Pharma (NASDAQ: BBIO): filings, earnings, deals and other events, from REDFILED.